» Articles » PMID: 33744974

Systematic in Vitro Specificity Profiling Reveals Nicking Defects in Natural and Engineered CRISPR-Cas9 Variants

Overview
Specialty Biochemistry
Date 2021 Mar 21
PMID 33744974
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Cas9 is an RNA-guided endonuclease in the bacterial CRISPR-Cas immune system and a popular tool for genome editing. The commonly used Streptococcus pyogenes Cas9 (SpCas9) is relatively non-specific and prone to off-target genome editing. Other Cas9 orthologs and engineered variants of SpCas9 have been reported to be more specific. However, previous studies have focused on specificity of double-strand break (DSB) or indel formation, potentially overlooking alternative cleavage activities of these Cas9 variants. In this study, we employed in vitro cleavage assays of target libraries coupled with high-throughput sequencing to systematically compare cleavage activities and specificities of two natural Cas9 variants (SpCas9 and Staphylococcus aureus Cas9) and three engineered SpCas9 variants (SpCas9 HF1, HypaCas9 and HiFi Cas9). We observed that all Cas9s tested could cleave target sequences with up to five mismatches. However, the rate of cleavage of both on-target and off-target sequences varied based on target sequence and Cas9 variant. In addition, SaCas9 and engineered SpCas9 variants nick targets with multiple mismatches but have a defect in generating a DSB, while SpCas9 creates DSBs at these targets. Overall, these differences in cleavage rates and DSB formation may contribute to varied specificities observed in genome editing studies.

Citing Articles

CRISPR-Cas9 target-strand nicking provides phage resistance by inhibiting replication.

Nguyen G, Schelling M, Sashital D bioRxiv. 2024; .

PMID: 39282300 PMC: 11398490. DOI: 10.1101/2024.09.05.611540.


CRISPR-Cas12a exhibits metal-dependent specificity switching.

Nguyen G, Schelling M, Raju A, Buscher K, Sritharan A, Sashital D Nucleic Acids Res. 2024; 52(16):9343-9359.

PMID: 39019776 PMC: 11381342. DOI: 10.1093/nar/gkae613.


CRISPR-Cas12a exhibits metal-dependent specificity switching.

Nguyen G, Schelling M, Buscher K, Sritharan A, Sashital D bioRxiv. 2023; .

PMID: 38076861 PMC: 10705449. DOI: 10.1101/2023.11.29.569287.


CRISPR-Cas effector specificity and cleavage site determine phage escape outcomes.

Schelling M, Nguyen G, Sashital D PLoS Biol. 2023; 21(4):e3002065.

PMID: 37058530 PMC: 10132644. DOI: 10.1371/journal.pbio.3002065.


The PROTECTOR strategy employs dCas orthologs to sterically shield off-target sites from CRISPR/Cas activity.

Sapozhnikov D, Szyf M Sci Rep. 2023; 13(1):2280.

PMID: 36759683 PMC: 9911626. DOI: 10.1038/s41598-023-29332-2.


References
1.
Doudna J . The promise and challenge of therapeutic genome editing. Nature. 2020; 578(7794):229-236. PMC: 8992613. DOI: 10.1038/s41586-020-1978-5. View

2.
Fu B, Smith J, Fuchs R, Mabuchi M, Curcuru J, Robb G . Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9. Nat Microbiol. 2019; 4(5):888-897. PMC: 6512873. DOI: 10.1038/s41564-019-0382-0. View

3.
Wang D, Zhang C, Wang B, Li B, Wang Q, Liu D . Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning. Nat Commun. 2019; 10(1):4284. PMC: 6753114. DOI: 10.1038/s41467-019-12281-8. View

4.
Horlbeck M, Witkowsky L, Guglielmi B, Replogle J, Gilbert L, Villalta J . Nucleosomes impede Cas9 access to DNA in vivo and in vitro. Elife. 2016; 5. PMC: 4861601. DOI: 10.7554/eLife.12677. View

5.
Lee J, Jeong E, Lee J, Jung M, Shin E, Kim Y . Directed evolution of CRISPR-Cas9 to increase its specificity. Nat Commun. 2018; 9(1):3048. PMC: 6078992. DOI: 10.1038/s41467-018-05477-x. View